WT1 and acute myeloid leukemia: We screened for mutations in a selected panel of genes (NPM1, CEPBA, FLT3, NRAS, KRAS, PTPN11, KIT and WT1) that were previously shown to associate with outcome in AML [11,18] in both the initial and corresponding relapse AML samples; results are shown in S1 Table.